Baseline patient and disease characteristics
| Characteristics . | FLT3-TKD+NPM1+ (N = 21) . | FLT3-TKD+ only (N = 18) . | P (FLT3-TKD+NPM1+ vs FLT3-TKD+) . | NPM1+ only (N = 117) . | P (FLT3-TKD+NPM1+ vs NPM1+) . | FLT3-ITD+NPM1+ (N = 107) . | P (FLT3-TKD+NPM1+ vs FLT3-ITD+NPM1+) . |
|---|---|---|---|---|---|---|---|
| Age, median (range), y | 60 (45-83) | 58 (28-84) | .34 | 63 (17-88) | .10 | 60 (23-86) | .44 |
| Sex, male, n (%) | 13 (62) | 8 (44) | .34 | 58 (50) | .63 | 38 (36) | .03 |
| WBC count, median (range), × 109/L | 3 (1-69) | 17 (1-103) | .16 | 7 (0-100) | .23 | 8 (0-378) | .17 |
| Platelet count, median (range), × 109/L | 25 (2-111) | 46 (12-217) | .045 | 45 (3-535) | .01 | 30 (1-326) | .45 |
| Hemoglobin, median (range), g/dL | 10 (8-13) | 10 (8-12) | .84 | 9 (7-14) | .67 | 9.5 (5-12) | .35 |
| ANC, median (range), × 109/L | 1 (0-13) | 0 (0-22) | .85 | 1.1 (0-23.3) | .40 | .4 (0-36) | .29 |
| BM blast, median (range), % | 82 (55-95) | 82 (22—94) | .52 | 69 (26-92) | .03 | 75 (21-97) | .45 |
| Absolute peripheral blast count, median (range), × 109/L | 37 (0-94) | 4.6 (0-95) | .59 | 19 (0-95) | .94 | 3 (0-367) | .06 |
| LDH, median (range), IU/L | 796 (483-3193) | 842 (390-9508) | .98 | 817 (315-11912) | .36 | 990 (424-6639) | .61 |
| Therapy-related AML status | 6 (29) | 6 (33) | >.99 | 21 (20) | .25 | 13 (12) | .09 |
| Cytogenetics | |||||||
| Adverse, n (%) | 1 (5) | 4 (22) | .18 | 6 (5) | .99 | 0 (0) | .16 |
| Intermediate, n (%) | 18 (95) | 14 (78) | 106 (95) | 97 (100) | |||
| Favorable, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
| Unevaluable metaphases, n | 2 | 0 | 5 | 10 | |||
| Mutations, n/N (%) | |||||||
| RAS | 5/21 (24) | 7/18 (39) | .49 | 33/116 (28) | .79 | 10/104 (10) | .13 |
| CEBPA | 2/19 (11) | 0/11 (0) | .51 | 10/87 (11) | .99 | 10/83 (12) | .99 |
| DNMT3A | 4/14 (29) | 2/7 (29) | 1.00 | 20/64 (31) | 1.00 | 21/69 (30) | .99 |
| IDH1/2 | 5/21 (24) | 2/11 (22) | >.99 | 30/91 (33) | .60 | 31/92 (34) | .45 |
| TP53 | 0/15 (0) | 0/7 (0) | >.99 | 3/56 (5) | >.99 | 2/59 (3) | >.99 |
| Induction regimens, n (%) | |||||||
| High/intermediate-intensity cytarabine-based regimens | 17 (81) | 12 (67) | .46 | 72 (62) | .14 | 75 (70) | .43 |
| Low-intensity–based regimens | 4 (19) | 6 (33) | 45 (38) | 32 (30) | |||
| Consolidation treatments among responders, n (%) | |||||||
| Chemotherapy | 8/17 (47) | 6/14 (43) | >.99 | 89/105 (85) | .001 | 49/90 (54) | .61 |
| Transplant | 9/17 (53) | 8/14 (57) | 16/105 (15) | 41/90 (46) | |||
| Characteristics . | FLT3-TKD+NPM1+ (N = 21) . | FLT3-TKD+ only (N = 18) . | P (FLT3-TKD+NPM1+ vs FLT3-TKD+) . | NPM1+ only (N = 117) . | P (FLT3-TKD+NPM1+ vs NPM1+) . | FLT3-ITD+NPM1+ (N = 107) . | P (FLT3-TKD+NPM1+ vs FLT3-ITD+NPM1+) . |
|---|---|---|---|---|---|---|---|
| Age, median (range), y | 60 (45-83) | 58 (28-84) | .34 | 63 (17-88) | .10 | 60 (23-86) | .44 |
| Sex, male, n (%) | 13 (62) | 8 (44) | .34 | 58 (50) | .63 | 38 (36) | .03 |
| WBC count, median (range), × 109/L | 3 (1-69) | 17 (1-103) | .16 | 7 (0-100) | .23 | 8 (0-378) | .17 |
| Platelet count, median (range), × 109/L | 25 (2-111) | 46 (12-217) | .045 | 45 (3-535) | .01 | 30 (1-326) | .45 |
| Hemoglobin, median (range), g/dL | 10 (8-13) | 10 (8-12) | .84 | 9 (7-14) | .67 | 9.5 (5-12) | .35 |
| ANC, median (range), × 109/L | 1 (0-13) | 0 (0-22) | .85 | 1.1 (0-23.3) | .40 | .4 (0-36) | .29 |
| BM blast, median (range), % | 82 (55-95) | 82 (22—94) | .52 | 69 (26-92) | .03 | 75 (21-97) | .45 |
| Absolute peripheral blast count, median (range), × 109/L | 37 (0-94) | 4.6 (0-95) | .59 | 19 (0-95) | .94 | 3 (0-367) | .06 |
| LDH, median (range), IU/L | 796 (483-3193) | 842 (390-9508) | .98 | 817 (315-11912) | .36 | 990 (424-6639) | .61 |
| Therapy-related AML status | 6 (29) | 6 (33) | >.99 | 21 (20) | .25 | 13 (12) | .09 |
| Cytogenetics | |||||||
| Adverse, n (%) | 1 (5) | 4 (22) | .18 | 6 (5) | .99 | 0 (0) | .16 |
| Intermediate, n (%) | 18 (95) | 14 (78) | 106 (95) | 97 (100) | |||
| Favorable, n (%) | 0 (0) | 0 (0) | 0 (0) | 0 (0) | |||
| Unevaluable metaphases, n | 2 | 0 | 5 | 10 | |||
| Mutations, n/N (%) | |||||||
| RAS | 5/21 (24) | 7/18 (39) | .49 | 33/116 (28) | .79 | 10/104 (10) | .13 |
| CEBPA | 2/19 (11) | 0/11 (0) | .51 | 10/87 (11) | .99 | 10/83 (12) | .99 |
| DNMT3A | 4/14 (29) | 2/7 (29) | 1.00 | 20/64 (31) | 1.00 | 21/69 (30) | .99 |
| IDH1/2 | 5/21 (24) | 2/11 (22) | >.99 | 30/91 (33) | .60 | 31/92 (34) | .45 |
| TP53 | 0/15 (0) | 0/7 (0) | >.99 | 3/56 (5) | >.99 | 2/59 (3) | >.99 |
| Induction regimens, n (%) | |||||||
| High/intermediate-intensity cytarabine-based regimens | 17 (81) | 12 (67) | .46 | 72 (62) | .14 | 75 (70) | .43 |
| Low-intensity–based regimens | 4 (19) | 6 (33) | 45 (38) | 32 (30) | |||
| Consolidation treatments among responders, n (%) | |||||||
| Chemotherapy | 8/17 (47) | 6/14 (43) | >.99 | 89/105 (85) | .001 | 49/90 (54) | .61 |
| Transplant | 9/17 (53) | 8/14 (57) | 16/105 (15) | 41/90 (46) | |||
ANC, absolute neutrophil count; BM, bone marrow; LDH, lactate dehydrogenase. WBC, white blood cell.